Help improve cancer early detection
Too often, cancer goes undetected until it is at an advanced stage. Thinking about the possibility of having cancer can feel overwhelming, but taking steps to catch cancer early can make you feel more in control of your health. The earlier that cancer can be found, the higher the chance of survival.
A blood test designed to detect multiple types of cancer
The PATHFINDER study will evaluate GRAIL’s multi-cancer early detection test Galleri™, an investigational test that has been designed to detect many types of cancer through one blood draw. The U.S. Food and Drug Administration has not yet approved this test for use outside of a research study. It is not meant to replace the cancer screening tests your healthcare provider may recommend, such as colonoscopy or mammography.
Galleri looks for signals of cancer that may be present in a person’s blood. If a signal that may be cancer is detected, the test is designed to identify the location in the body the signal may be coming from, for example, the lungs or the colon. This information helps healthcare providers determine the appropriate tests to confirm whether cancer is present. GRAIL’s multi-cancer early detection test does not measure your genetic risk of developing cancer in the future.
OHSU is one of seven national study sites
The OHSU Knight Cancer Institute is one of seven sites across the country selected by GRAIL, Inc., a health care company dedicated to detecting cancer early, to join a study designed to improve early detection of cancer. The PATHFINDER study is locally overseen by Tom Beer, M.D., deputy director of the OHSU Knight Cancer Institute and chief medical officer for the institute's Cancer Early Detection Advanced Research (CEDAR) program.